Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - New Medicine 1/2003, s. 44-47
Paweł Bernat, Radosław Pietura, Małgorzata Szczerbo-Trojanowska
Application of T1- and T2-weighted magnetic resonance imaging (MRI) in assessment of uterine leiomyoma morphology after uterine artery embolisation
Department of Interventional Radiology and Neuroradiology Medical University of Lublin
Summary
Objective: To evaluate the application of T1- and T2-weighted magnetic resonance imaging (MRI) in assessment of uterine leiomyoma morphology after uterine artery embolisation.
Methods: Between November 2001 and January 2003 MR examination was performed on 110 patients. T1-weighted and T2-weighted spin-echo MR images were made through the pelvis in sagittal, tranverse, coronal planes before the procedure, and 3 months after. Fifty-eight % of leiomyomas gave an iso- or hyperintensive signal in T2-weighted imaging. The mean uterine volume was 496 cm3 and the mean volume of the dominant fibroid was 198 cm3. Leiomyoma was submucosal in 63% of patients, transmural in 13%, and subserosal in 24%.
Results: After 3 months, MRI showed the mean volume reduction of the dominant fibroid to be 57%, ranging from 36% to 89%, and of the uterus to be 41%, ranging from 30% to 73%. In T1-weighted MR images submucosal-expelling fibroids showed hyperintensive signal, and only long-term changes in morphology could have been observed. T2-weighted MR images were used in evaluation of volume reduction and the detailed morphology of the fibroids.
Conclusions: A T2-weighted MR sequence is an effective method for the assessment of the morphology of uterine leiomyoma, the T1-weighted sequence being used in imaging of submucosal – expelling fibroids.
INTRODUCTION
Uterine artery embolisation is a less invasive treatment for symptomatic uterine leiomyoma, and is increasingly popular. Indications for the therapy include abnormal uterine bleeding (menorrhagia and metrorhagia), and bulk-related syndromes (pain, increased urinary frequency, nocturia, constipation, patient discomfort) caused by one or more fibroids (6). Since 1995, when Ravine first described uterine artery embolisation, plenty of subsequent published studies have shown embolisation to be effective in the treatment of heavy menstrual bleeding (90%, 92%) and of bulk symptoms (93%, 92%) – data are based on analyses of 200-400 patients treated with uterine artery embolisation and observed over a minimum of 12 months (8, 11, 17, 18).
In Poland, uterine artery embolisation was performed for the first time in November 2001 at the Medical University of Lublin (16). A decrease in, or lack of, symptoms as a result is long-lasting (21). The most dangerous side-effect of embolisation is uterine abscess, which indicates definitive hysterectomy (15). Its frequency has been estimated as 1 per 100 and as 1 per 700 treatments (18, 20). Sometimes, from one to four months after treatment, parts of submucosal leiomyoma may be expelled into the uterine cavity and progress to the vagina. This condition is associated with pain and a slight temperature. No case has been published describing an enlarged leiomyoma or the appearance of a new leiomyoma after embolisation. The only method used for qualification for the procedure is magnetic resonance imaging (MRI). MR imaging is much more sensitive and specific than transvaginal ultrasound examination in diagnosing adenomyosis, which may occur at the same time in as many as 20% of patients with leiomyoma (2). MR examination also allows the exclusion of other disorders, such as sarcoma or tumours of ovary. The aim of this paper is to evaluate the application of T1- and T2-weighted magnetic resonance imaging (MRI) in the assessment of the morphology of uterine leiomyoma after uterine artery embolisation.
MATERIALS AND METHODS

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1

19

Wybieram
  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2

49

Wybieram
  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3

119

Wybieram
  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
Piśmiennictwo
1. Andrews R.T. et al.: Successful embolisation of collateral from the ovarian artery during uterine artery embolization for fibroids: a case report. J. Vasc. Interv. Radiol. 2000; 11:607-610. 2. Ascher S.M. et al.: Adenomyosis: prospective comparison of MR imaging and transvaginal sonography. Radiology 1994; 190:803-806. 3. Berkowitz R. et al.: Vaginal expulsion of submucosal fibroids after uterine artery embolization: a report of three cases. J. Reproduct. Med. 1999; 44:373-376. 4. Broder M.S. et al.: The Appropriateness of Recommendations for Hysterectomy. Obstet Gynecol. 2000; 95:199-205. 5. Common A.A. et al.: Therapeutic failure of uterine fibroid embolisation caused by underlying leiomyosarcoma. J. Vasc. Interv. Radiol. 2001; 12:1449-1452. 6. Goodwin S.C. et al.: Uterine artery embolization for the treatment of uterine leiomyomata, midterm results. J.Vasc. Interv. Radiol. 1999; 10:1159-1165. 7. Goto A. et al.: Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its izosymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Intern. J. Gynecol. Cancer 2002; 12(4):354-358. 8. Hutchins F. et al.: Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri. J. Am. Assoc. Gynecol. Laparosc. 1999; 6:279-284. 9. Leibsohn S. et al.: Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomatas. Am. J. Obstet. Gynecol. 1990; 162:968-976. 10. Levine D. et al.: Obstetrics MR imaging Radiology 1999; 211:609-617. 11. McLucas B. et al.: Uterine Fibroid Embolization: Nonsurgical treatment for symptomatic fibroids. J. Am. Coll. Surg. 2001; 192:95-105. 12. Omary R.A. et al.: The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids. J. Vasc. Interv. Radiol. 2002; 13:1149-1153. 13. Outwater E.K. et al.: Adenomyosis: current concepts and imaging considerations. AJR 1998; 214:437-441. 14. Pelage J. et al.: Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and midterm follow-up. Radiology 2000; 215:428-431. 15. Pietura R. et al.: Zabieg embolizacji tętnic macicznych jako alternatywna metoda leczenia mięśniaków macicy. Ginekologia Polska 2003; 1,79-84. 16. Pietura R. i wsp.: Opis przypadku chorej z objawowym mięśniakiem macicy leczonej metodą embolizacji tętnic macicznych. Ginekol. Pol. 2003; 1:69-72. 17.Ravina J.H. et al.: Arterial embolisation to treat uterine myomata. Lancet 1995; 364:71-72. 18. Spies J. et al.: Uterine Artery Embolization for Leiomyomata. Obstet Gynec. 2001; 98:29-34. 19. Spies J. et al.: Complications after uterine artery embolization for Leiomyomas. Obstet Gynec. 2002; 100:873-880. 20. Walker W.J., Pelage P.: Uterine artery embolization for symptomatic fibroids: clinical result in 400 women with imaging follow-up. Brit. J. Obstet. Gynaecol. 2002; 109:1262-1272. 21.Worthington-Kirsch R.L. et al.: Uterine arterial embolization for the management of leiomyomas: quality of life assessment and clinical response. Radiology 1998; 208:625-629. 22. Zawin M. et al.: Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertility and Sterility 1998; Vol 70, NO.3.
New Medicine 1/2003
Strona internetowa czasopisma New Medicine